Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Medical Officer | September 07, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date September 07, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 59,882 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-07 · Exercise / conversion · Acquired 1,667 · Balance 60,753 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-09-08 · Sale · Disposed 871 · Balance 59,882 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-07 · Exercise / conversion · Disposed 1,667 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2019 Filed Dec 5, 2019 18:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-059250 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 01:49 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseOrdinary Shares | 1,960 | $28.17 | $55,213.20 |
DisclosureSEC source: 0001209191-19-057692 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Mark Schoenberg Pension Plan FBO Mark Schoenberg Disclosed balance after: 7,967 Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 13:27 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 1,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-048672 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,209 Underlying: Ordinary Shares · 1,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 13:27 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 343 | $33.92 | $11,634.56 |
DisclosureSEC source: 0001209191-19-048672 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,007 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 13:27 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-048672 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:21 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035245 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:21 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Tax withholdingOrdinary Shares | 343 | $35.05 | $12,022.15 |
DisclosureSEC source: 0001209191-19-035245 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,309 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:21 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-035245 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 23:42 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseOrdinary Shares | 272 | $37.01 | $10,066.45 |
DisclosureSEC source: 0001209191-19-021092 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 F1 · kind: The reporting person's purchase of Ordinary Shares of the Issuer reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's sale of 272 Ordinary Shares of the Issuer at a price of $37.30 per share on March 6, 2019. The reporting person has agreed to pay to the Issuer $79.15, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 02:46 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,991 | $37.30 | $74,264.30 |
DisclosureSEC source: 0001209191-19-017933 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,338 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| March 04, 2019 Filed Mar 8, 2019 02:46 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017933 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,292 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years, with the issuance of the underlying shares for the March 4, 2019 installment delayed until March 5, 2019. F3 · derivative.expiration_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years, with the issuance of the underlying shares for the March 4, 2019 installment delayed until March 5, 2019. Read SEC document |
| March 04, 2019 Filed Mar 8, 2019 02:46 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-017933 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:24 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005801 · doc4.xml · derivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:24 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001209191-19-005801 · doc4.xml · derivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Ordinary Shares · 7,500 shares Expires 2029-01-26 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.